key: cord-0693404-914lwoo4
authors: Qing, Enya; Kicmal, Tom; Kumar, Binod; Hawkins, Grant M.; Timm, Emily; Perlman, Stanley; Gallagher, Tom
title: Dynamics of SARS-CoV-2 Spike Proteins in Cell Entry: Control Elements in the Amino-Terminal Domains
date: 2021-08-03
journal: mBio
DOI: 10.1128/mbio.01590-21
sha: 2f38e634ba02e64da31e4d8d935c2d23ce0f9d59
doc_id: 693404
cord_uid: 914lwoo4

Selective pressures drive adaptive changes in the coronavirus spike proteins directing virus-cell entry. These changes are concentrated in the amino-terminal domains (NTDs) and the receptor-binding domains (RBDs) of complex modular spike protein trimers. The impact of this hypervariability on virus entry is often unclear, particularly with respect to sarbecovirus NTD variations. Therefore, we constructed indels and substitutions within hypervariable NTD regions and used severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus-like particles and quantitative virus-cell entry assays to elucidate spike structures controlling this initial infection stage. We identified NTD variations that increased SARS-CoV-2 spike protein-mediated membrane fusion and cell entry. Increased cell entry correlated with greater presentation of RBDs to ACE2 receptors. This revealed a significant allosteric effect, in that changes within the NTDs can orient RBDs for effective virus-cell binding. Yet, those NTD changes elevating receptor binding and membrane fusion also reduced interdomain associations, leaving spikes on virus-like particles susceptible to irreversible inactivation. These findings parallel those obtained decades ago, in which comparisons of murine coronavirus spike protein variants established inverse relationships between membrane fusion potential and virus stability. Considerable hypervariability in the SARS-CoV-2 spike protein NTDs also appear to be driven by counterbalancing pressures for effective virus-cell entry and durable extracellular virus infectivity. These forces may selectively amplify SARS-CoV-2 variants of concern.

such that by late 2020, less than 1 year into the CoV disease 2019 (COVID-19) pandemic, SARS-CoV-2 variants dominated the human-circulating virus population. The current SARS-CoV-2 viruses are now classified onto several variants of concern (VOCs) due to their high transmissibility, their potential for bypassing natural infection and vaccine-induced immunity, and their possibly increased virulence (5) .

The concerning SARS-CoV-2 variations are within the viral spike (S) proteins. Intercellular and human-to-human transmission requires S proteins, as they direct virus entry into oro-nasal, airway, and alveolar epithelial cells (6) (7) (8) . The S proteins are complex ;500-kDa homo-trimers, operating as molecular machines that bind viruses to target cells and catalyze the fusion of virus and cell membranes. These functions are executed by several S protein domains that are arranged into metastable "prefusion" configurations. Multidomain S1 portions that are distal from the virion envelopes bind to attachment factors and bona fide protein receptors (9, 10) . Binding reorients S1 relative to virion-proximal S2 portions (11, 12) , allowing S2 to extend, capture cell membranes via hydrophobic fusion peptides, and then pull cell and virus membranes into proximity, through a refolding process that ends in membrane fusion and stable "postfusion" helical bundles (13, 14) . Pre-and postfusion S protein structures (15, 16) , structural intermediates on the refolding pathway (13, 17) , and adaptive variations impacting the refolding process (18) (19) (20) indicate that these cell entry dynamics are under powerful selective forces, potentially influencing CoV transmissibility.

Numerous substitutions and deletions have been identified in the S proteins of viruses associated with the COVID19 pandemic (21, 22) . Our broad aims were to identify those consequential changes that alter the dynamics of virus-cell entry and infection. To this end, we focused on comparing SARS-CoV-2 S with the S proteins of related sarbecoviruses. There are notable distinctions. First, SARS-CoV-2 S proteins have S1 amino-terminal domain (NTD) loops that are divergent both in sequence and in length from those of other sarbecoviruses (23; see also Fig . S1 in the supplemental material). Second, SARS-CoV-2 proteins have structurally divergent S1 receptor-binding domains (RBDs) that bind with relatively high affinity to human angiotensin-converting enzyme 2 (hACE2) (23, 24) . Third, unlike several related sarbecoviruses, SARS-CoV-2 S proteins contain a substrate site for cleavage by the cellular protease furin, which upon proteolysis divides S protomers into noncovalently associated S1 and S2 portions (25, 26) .

In strong support of the biological significance of these three distinctive features, recent highly transmissible variants of concern harbor deletion and substitution mutations in all three regions (5) . Of these three regions, two are partially understood in mechanistic detail: the affinity of the RBD-hACE2 interactions (27, 28) and the proteolytic cleavage into S1 and S2 fragments (25, 26) , both of which are considered relevant to SARS-CoV-2 human emergence and transmission. This leaves the operating mechanisms of the divergent NTD loops open to further investigation. The NTD loops may be part of a structure that binds viruses to attachment factors, of which there are several candidates (29) (30) (31) (32) (33) , each potentially imposing selective forces. The NTD loops are recognized by virus-neutralizing antibodies (34, 35) , making it possible that immune pressures drive their divergence into alternative structures. Yet another possibility is that the NTDs operate to control S protein unfolding transitions required for virus-cell entry (36) . Here, we explored the last possibility. We generated results implicating SARS-CoV-2 NTDs in the cell binding and membrane fusion stages of virus entry.

Hypervariability in coronavirus spike NTDs. CoV S proteins are among the most variable coronavirus-encoded proteins. Of note, S protein variability includes both indels and substitutions. Indels, generated by discontinuous CoV transcriptional processes (37) , are concentrated in S protein NTDs and RBDs, and they stand out as key features of variability in all four betacoronavirus groups (see Fig. S1 in the supplemental material). Several decades ago, the biological significance of vestigial RBD indels was investigated in some of the embecoviruses, where specific indels were correlated with S protein stability and reduced spike-directed membrane fusion catalysis (38, 39) . However, the effects that NTD indels may have on S protein structural dynamics and catalytic function remain unclear.

Both NTD and RBD indels distinguish several sarbecovirus S proteins (22) (Fig. S1 ). In a comparison of SARS-CoV-1 and SARS-CoV-2, NTD variations are evident at three locations, highlighted in red, blue, and purple in Fig. 1a and b. Both substitutions and indels are evident. Perhaps expectedly, the sites of substitution and indel hypervariability are poorly resolved in structures of stabilized SARS-CoV-2 ectodomains (13, 23, 24) . The variable regions are therefore sketched as dotted lines in Fig. 1a , with each dotted line forming a loop. The three loops together form a prominence at the distal part of each NTD (cyan and dotted loops in Fig. 1a ). Of note, this region is part of a SARS-CoV-2 antigenic supersite (40, 41) .

Guided by the SARS S structures and the primary sequence variabilities, we exchanged nucleotide sequences encoding these hypervariable portions of the NTDs. In this way, we expected to preserve the SARS-1 and SARS-2 NTD core structures while varying distal loop length and composition. Specifically, the smaller SARS-1 regions from residues 71 to 75 (loop 1), 141 to 157 (loop 2), and 236 to 248 (loop 3) were reciprocally exchanged with larger SARS-2 regions from residues 67 to 78 (loop 1), 144 to 164 (loop 2), and 243 to 261 (loop 3). The exchanged residues did not include any cysteines and did not generate alternative N-glycosylation patterns in the recombinant proteins.

We compared the S proteins as isogenic pairs, as illustrated in Fig. 1c . SARS-1 S was compared to SARS-1/2 (SARS-1 with the larger SARS-2 loops). Conversely, SARS-2 S was compared with SARS-2/1 (SARS-2 with the smaller SARS-1 loops). We also introduced a SARS-2 S-stabilizing D614G change (4) into SARS-2 and SARS-2/1 ( Fig. 1a ; protomer alpha carbon tracing). These constructs were designated D614G-2 and D614G-2/1, respectively (Fig. 1c) . Inclusion of the D614G substitution allowed us to consider potential epistatic NTD-D614G control mechanisms.

Hypervariable NTD loops control S protein stability and membrane fusion potential. We utilized a coronavirus-like particle (VLP) platform to determine whether the reciprocal exchanges of NTD loop regions affect changes to virus infection stages. VLPs allowed us to track S proteins through the stages of virus particle assembly, secretion from producer cells, extracellular particle stability, and subsequent particle entry into target cells through virus-cell membrane fusion. To produce VLPs incorporating the various SARS-1 and SARS-2 S variants, each S gene construct was combined with the SARS-CoV-2 E (envelope), M (membrane), and N (nucleocapsid) genes, and the four were then cotransfected into HEK293T cells. The N genes were engineered to include a nanoluciferase (Nluc) "HiBiT" fragment (42, 43) , making it so that transfected cells produced and secreted HiBiT-N-containing VLPs. Secreted VLPs were harvested and purified using size exclusion chromatography (Fig. 2a) . Notably, the VLPs were readily detectable throughout these particle purification procedures by complementing the internal HiBiT tags with Nluc "LgBiT," which forms an easily quantified Nluc enzyme activity ( Fig. 2a and references 42 and 43) .

Western immunoblotting demonstrated that all VLPs contained virion S, E, M, and N proteins, supporting the contention that VLPs are faithful reflections of authentic SARS-CoV-2 virions (43) . Here, we focused further on VLP S proteins, as well as S proteolytic cleavage products S1 and S2, so that S1-S2 heterodimer stabilities might be assessed. We found that the NTD exchange had relatively little effect on N-to-S ratios in the context of SARS-1 (Fig. 2b) . SARS-1 S proteins remain largely uncleaved throughout particle genesis and secretion (44) , and therefore, S1 fragments were not abundant on the purified VLPs (Fig. 2b) . However, SARS-2 S proteins are subject to furin-mediated cleavage (23) , making for prominent VLP-associated S1 and S2 (Fig. 2e) . For SARS-2, the NTD exchange in SARS-2/1 effected a profound S protein alteration that was most evident by the nearly complete absence of S1 on VLPs (Fig. 2e ). This instability was not observed with VLPs harboring the D614G substitution (Fig. 2h) . In fact, in relation to the N proteins that serve as internal standards, the D614G-2/1 VLPs had more intact (Continued on next page) Qing et al. S1-S2 heterodimers than any of the variants analyzed in this study (Fig. 2h) . These findings demonstrate that the sequence and length of hypervariable NTD loops control S protein heterodimer stabilities.

The HiBiT-containing VLPs were used to evaluate CoV cell entry in biosafety level 1 (BSL-1) assays that specifically isolate the initial cell entry stage of infection. First, we constructed clones encoding hACE2 with cytoplasmic (carboxy-terminal) LgBiT and then introduced hACE2-LgBiT and hTMPRSS2 cDNAs into HeLa cells to generate virus susceptibility (45) . Next, we inoculated the cells with HiBiT VLPs and quantified HiBiT-LgBiT complementation (Nluc accumulation) over time. Using the normalized Nluc levels as a measure of successful VLP cell entry, we noted that NTD modifications in the SARS-1 background had no effect on VLP cell entry (Fig. 2c) . In contrast, the NTD modifications in the SARS-2 background had profound effects. Relative to parental SARS-2, NTD-altered SARS-2/1 had ;10-fold less entry (Fig. 2f ). This finding was consistent with the loss of S1 from the NTD-altered VLPs (Fig. 2e ). The D614G substitution had a notable restorative effect. Relative to parental D614G-2, the NTD-altered D614G-2/1 had ;3-fold more entry (Fig. 2i) , consistent with S1 retention on the NTD-altered VLPs (Fig. 2h) . These findings ascribe both loss-and gain-of-function properties to changes in the distal NTD loops of SARS-CoV-2.

VLP cell entry required hACE2 and hTMPRSS2 on target cells. It is known that hACE2 incorporates into extracellular vesicles (EVs) and secretes from cells (46) . We found that EVs with incorporated ACE2-LgBiT were readily harvested and purified from target cell supernatants ( Fig. S2a and b) . This prompted us to consider whether ACE2-containing EVs might substitute for target cells, making for cell-free assays of VLP fusion with EV target membranes. We incubated purified ACE2-LgBiT EVs with HiBiT VLPs, using trypsin in place of hTMPRSS2 to cleave/activate S protein fusion catalysis (47) , and then measured fusion-dependent complementation of HiBiT and LgBiT into Nluc. This cellfree VLP-EV fusion assay was highly sensitive, revealing VLP fusion signals nearly 3 log 10 over background, with the signals being linearly proportional to VLP concentration over a 2.5-log 10 range ( Fig. S2c and d) . Using this cell-free assay format, pairwise comparisons of VLPs were made, as schematized in Fig. 1c . SARS-1 and SARS-1/2 VLP fusions were indistinguishable (Fig. 2d) , SARS-2 VLP fusion exceeded that of SARS-2/1 by ;10-fold (Fig. 2g) , and D614G-2 fusion trailed that of D614G-2/1 by ;3-fold (Fig. 2j) . These findings accorded with TMPRSS2-activated cell entry data (Fig. 2c , f, and i). Together, the results in Fig. 2 demonstrate that NTD loops control S1-S2 heteromeric stability and membrane fusion potential.

Hypervariable NTD loops control RBD exposure. The complete separation of S1 from virus particles is a near-end-stage event in the transition from pre-to postfusion S protein conformations, coming only after more subtle NTD and RBD rearrangements (13, 17, 48) . We aimed to further understand how NTD loops influence the conformational changes that precede S1 separation. Among these rearrangements are the dynamic RBD elevations that position the S proteins for hACE2 receptor interactions (47, 49) . We compared the RBD dynamics on D614G-2 and D614G-2/1 VLPs, because these two variants have similar S1-S2 densities yet differ in NTD loops and ACE2-dependent cell entry activities. To compare RBD positioning, we introduced soluble hACE2-Fc receptors into cell-free fusion assays (Fig. 2j) and assessed soluble receptor interference. Interference with D614G-2/1 (50% inhibitory concentration [IC 50 ] = 5 nM) was 2-fold greater than with D614G-2 ( Fig. 3a and b) . As the two VLPs have identical RBDs, this finding argues that changes in the hypervariable NTD loops can control RBD repositioning into the standing states that bind ACE2. Recurrent display of elevated RBDs to target cell ACE2 may explain the gain of D614G-2/1 VLP cell entry function.

Similar cell-free fusion assays were performed in the presence of an RBD-specific monoclonal antibody (MAb). Relative to D614G-2 VLPs, the recombinant D614G-2/1 VLPs were moderately more sensitive to neutralization ( Fig. 3c and d) . These findings further support the contention that hypervariable NTD loops control RBD exposures.

Hypervariable NTD loops and protease exposure. During transitions toward membrane fusion, S proteins are cleaved by host proteases at a site that is largely buried in the prefusion state (23, 50) . Cleavage at this "activating" S29 site is required to unleash S proteins for subsequent membrane fusion-catalyzing rearrangements. We aimed to determine whether NTD loops influence S29 substrate site exposure. We compared two VLP pairs for S29 cleavage-dependent fusion activation: SARS-2 with SARS-2/1 and D614G-2 with D614G-2/1. In cell-free fusion assays, trypsin cleaved ACE2-associated VLP S proteins at two positions, one consistent with scission at the activating S29 site (Fig. 4a) . To identify VLP sensitivity to this S29 cleavage, trypsin was titrated over a after 2 days, and HiBiT-VLPs were purified by size exclusion chromatography. VLPs were compared as isogenic pairs: SARS-1 versus SARS-1/2 (panels b to d), SARS-2 versus SARS-2/1 (panels e to g), and D614G-2 versus D614G-2/1 (panels h to j). Each pair was evaluated by Western blot (left), cell entry (middle), and cell-free fusion (right) assays. Western blot assays detected uncleaved S (S-unc), S1, S2, and HiBiT-N. Cell entry assays detected HiBiT-VLP entry into ACE2-LgBiT/hTMPRSS2 target cells. The cell entry data are presented relative to the cell entry of control inoculations of spikeless (No S) VLPs. Cell-free fusion data are presented as HiBiT-VLP:ACE2-LgBiT EV fusion levels relative to data under control conditions with spikeless VLPs. For the cell entry and cell-free fusion data, the error bars present standard deviations (SD) from three technical replicates (n = 3), with data being representative of three biological repeats.

NTD Control of SARS-CoV-2 Stability and Cell Entry ® 7-log 10 range and the cell-free fusions resulting from the trypsin cleavages were then measured. The SARS-2/1 VLPs were convincingly hypersensitive to trypsin-mediated fusion activation (Fig. 4b) . From the titration data, fusion-activating trypsin concentrations were defined in terms of the 50% effective concentration (EC 50 ) (Fig. 4c) , revealing that the highly labile SARS-2/1 VLPs with unstable S1-S2 heterodimers were ;100 times more sensitive to proteolytic activation than the other three more stable VLPs. These findings suggest that selective forces driving S protein stability oppose those forces driving facile proteolytic activation of membrane fusion.

S protein domain exposures and virus vulnerability. A propensity for RBD and protease substrate exposure can facilitate virus-cell entry but may leave extracellular viruses vulnerable to inactivation. We were surprised that D614G-2/1 VLPs appeared as exceptions to this pattern, as these particles exhibited more RBD exposure and more cell entry than parental D614G-2, all without compromising VLP stability. We further evaluated the maintenance of D614G-2/1 VLPs and found that they were indeed identical to parental D614G-2 in thermal (37°C) stability over a 40-h time period (Fig. S3) . However, the D614G-2/1 particles were notably fragile under certain experimental conditions. Upon centrifugation through sucrose cushions, D614G-2/1 VLPs lost S1 (Fig. 5a) and in turn had diminished capacity for cell entry (Fig. 5b) and cell-free membrane fusion (Fig. 5c) . Thus, the pattern holds; selective pressures for effective cell entry oppose those instilling S protein stability. Hypervariable NTD loops and virus attachment to target cells. While the collective results indicated that NTD loops control S protein stability, virus-cell entry, and virus-cell membrane fusion, they did not discount additional roles in direct virus-cell attachment. It remained possible that the high cell entry potential of D614G-2/1 VLPs (Fig. 2i) came from SARS-2/1 exchanges that increased direct NTD-cell binding. CoV NTDs do indeed attach to cell surface carbohydrates (51, 52) or proteins (53, 54) , and the SARS-CoV-2 NTDs in particular are proposed ligands for carbohydrates (31, 32) and proteins (29, 30) . To determine whether NTDs operate in virus-cell binding, SARS-CoV-2 NTD-2:Fc and RBD-2:Fc proteins (Fig. 6a) were introduced during SARS-CoV-2 pseudoparticle (PP) transductions. Transductions into human airway-derived Calu-3 cells, which are hACE2 positive and highly susceptible to SARS-CoV-2 (25, 45) , were reduced significantly by RBD-2:Fc, but not by NTD-2:Fc (Fig. 6b) . Similar findings came from evaluation of HeLa-hACE2 cells, where RBD-2:Fc but not NTD-2:Fc interfered with S protein-mediated fusion into syncytia (Fig. 6c) . While these results argued against a role for NTDs in virus-cell entry, it was possible that RBD:hACE2 interactions dominated the S-mediated entry and cell fusion processes, leaving no observable role for NTDs. HeLa cells express endogenous hACE2 at low levels, below that required for SARS-CoV-2 infection (1) but not so low as to preclude S protein-mediated fusion of the cells into syncytia (42) . With HeLa cells, NTD-2:Fc reduced S-mediated cell fusions by about 30%, while NTD-2/1:Fc, which displays altered SARS-1 NTD loops, effected no change in fusions (Fig. 6d) . While these findings indicate that the larger NTD-2 domains contribute moderately to S protein binding to HeLa cells, they do not support suggestions that direct binding of the smaller NTD-2/1 accounts for the enhanced entry and fusion potential of the D614G-2/1 variant. We conclude that the NTD variations evaluated in this study increase virus entry by mechanisms unrelated to direct NTD attachment to cells.

Metastable viruses are durably enclosed extracellular particles yet poised for opening at cell entry. The CoV S proteins directing this opening process must maintain both stable extracellular native (prefusion) states and dynamic responses to target cell NTD Control of SARS-CoV-2 Stability and Cell Entry ® receptors and proteases during virus-cell entry. Harsh extracellular environments select against S protein mobilities that can spontaneously inactivate viruses, while facilitated cell entry selects for S protein flexibilities that reveal receptor-binding and membrane fusion domains. These opposing selective pressures drive adaptive variations that rebalance metastable "set points." For example, murine CoVs acquire S protein deletions during cell culture passaging, acquiring extracellular stability with concomitant reductions in membrane fusion triggering (38, 39, 55, 56) . Adaptive changes in Middle East respiratory syndrome CoV (MERS-CoV) also change S-mediated fusion thresholds (57, 58) . More recent studies of SARS-CoV-2 revealed cell culture adaptations that include deletions of furin protease substrates, with resultant uncleaved S proteins stabilized against S1 shedding but concomitantly less susceptible to TMPRSS2 cleavage activation of membrane fusion (26, 59, 60) . The now-prevalent D614G change in SARS-CoV-2 also stabilizes S proteins noncovalently, promoting S1 retention (4, 36) and extracellular infectivity (20, 61) , but potentially with reduced susceptibility to activating serine proteases (62) .

This report identifies another locus of S protein variation that controls CoV metastability. The control elements were in hypervariable SARS-CoV-2 NTD loops, an unanticipated location that is distant from receptor-binding and activating protease substrate sites and also far from S protein interdomain connections. In speculating on how NTD loops operate indirectly to control S protein stability, we noted that the loops are not visible in cryoelectron microscopy (cryo-EM) images of unliganded S proteins (17, 24) but are resolved when fixed into position by bound neutralizing antibodies (35) . One conjecture is that restriction of the normally dynamic loops by antibodies, or by deletion of flexible glycine-rich stretches (Fig. 1) , rigidifies the NTDs more globally or changes the pitch of NTDs relative to the 3-fold S trimer axes, which in turn distorts the interdomain contacts regulating S1-S2 separation and resultant virus fusion. SARS-CoV-2 NTDs do indeed contact "630 loops" that control interdomain connections at critical S1-S2 interfaces (36) . The hypervariable NTD regions regulated these interdomain contacts, in that they impacted both hACE2:Fc binding and S1-S2 separation, which we interpret as NTD control of the more C-terminal RBDs into ACE2-accessible "up" orientations (47) . With RBDs "up" and then maintained in this position by bound ACE2, interdomain contacts further rearrange to permit membrane fusion and nearend-stage S1 shedding (49, 63) . Our results appear consistent with NTDs and RBDs operating cooperatively to reveal receptor-binding and membrane fusion-catalyzing elements in the S proteins. Future atomic-resolution imaging will be necessary to shed more light on cooperative NTD and RBD rearrangements.

The impact of NTD hypervariability depends on the S protein background. For the uncleaved SARS-CoV ("SARS-1") S proteins, NTD loop exchanges did not effect measurable changes in VLP entry and membrane fusion. We suggest that the stability of SARS-1 S is controlled by covalent S1-S2 linkage and other interfaces that are not influenced by distal NTD loops. For cleaved SARS-CoV-2 ("SARS-2") S proteins, the NTD loop exchanges were profoundly destabilizing, but the D614G substitution that is known to connect S1 and S2 (4) and enhance virus transmissibility (3, 64, 65) restored the prefusion S1-S2 structure. S structures show that the D614G change allows packing of "630 loops" between NTD and CTD1 domains (36) , and functional data correlate this interdomain packing with S1-S2 stability, even when one S protomer has an RBD in a precarious "up" position (66) . Although NTD loop-altered SARS-2 S structures are not yet available, we speculate that the NTD loops further adjust these D614G-630 loop control elements in ways that generate gain-of-function S proteins with enhanced hACE2 binding and membrane fusion characteristics. Taken in light of SARS-CoV-2 evolution through 2020, we further speculate that the initial springtime 2020 expansion of D614G variant SARS-CoV-2 generated overstabilized viruses that could accommodate adaptive destabilizing changes in NTDs and possibly other S domains. In fact, NTD indels in SARS-CoV-2 variants of concern were observed only after the stabilizing D614G substitution (67) . That a genetic drift around metastable set points can potentially generate hyper-fusogenic CoVs with enhanced cell entry potential is an important consideration in understanding CoV cell entry, transmission, and pathogenicity.

This report also highlights relationships between enhanced cell entry potential and virus stability. The D614G VLPs harboring the smaller NTD loops showed enhanced hACE2 interactions and increased cell entry, yet they were unstable and shed S1 during a relatively gentle VLP purification process (Fig. 5) . Similarly, the SARS-2 VLPs with the smaller NTD loops showed dramatically higher sensitivity to fusion-activating trypsin protease (Fig. 4) , making them potentially capable of broad cell entry, yet they were so unstable that their entry potential decayed rapidly in cell culture media. These findings highlight the opposing selective pressures that bear on CoVs as they adapt in nature.

NTD hypervariability may also be driven by selective binding to host cell attachment factors. Indeed, our original hypothesis was that the hypervariable NTD loops are part of a cell-binding motif, given their distal location on the S protein trimers (Fig. 1) and given that the NTDs of other beta-CoVs are established cell receptor-binding domains (52, 54) . Exploring this hypothesis, we obtained evidence that the NTDs bind to cell surfaces (Fig. 6) . DC-SIGN may be an NTD attachment factor, as it binds SARS-CoV (68) and was recently shown to interact with SARS-CoV-2 at glycan N149 (29), a residue within NTD loop 2. Very low levels of HeLa cell surface DC-SIGN (69) might explain the modest NTD binding. Alternatively, sialic acids may be virus-binding ligands, as they have been recently proposed to bind at or near residues comprising NTD loop 1 (32) . Other putative NTD-interacting factors (30, 31) are possible host factors, as are NTD-directed allosteric effects that influence cell attachment through other S protein domains (70) . While we did not find evidence favoring direct NTD cell binding as a step toward enhanced entry (Fig. 6) , we remain open to NTD-facilitated virus entry in other contexts. Other infection contexts may even reveal that NTD cell binding reorients RBDs and fusion domains for effective entry.

The COVID-19 pandemic is now dominated by several variants of concern (VOCs) (5). Among these VOCs, several have NTD deletions; for example, the prevalent B.1.1.7 variant has deletions of residues 69 to 70 and 144 to 145 within NTD loops 1 and 2, respectively (71) (Fig. 1 and see Fig. S4 in the supplemental material). Furthermore, viral RNAs have been isolated from persistently infected patients, with sequencing revealing in-frame recurrent deletion regions (RDRs) at or near the same three NTD loops that were evaluated in our study (22) (Fig. S4) . In correlating the results of our study with these recurrent NTD deletions, we must note our limitations. First, our study does not investigate NTD changes in the context of authentic, replication-competent SARS-CoV-2. However, we emphasize that the VLPs employed in this study faithfully reflect authentic SARS-CoV-2 entry far more closely than that of frequently employed pseudo-SARS-2 viruses (42, 43) (Fig. S5) . The cell-free VLP fusion assays utilized in this study also have broad utility, in that CoV entry can be analyzed quantitatively in carefully controlled in vitro settings. Furthermore, as noninfectious BSL-1 surrogates of SARS-CoV-2, the VLPs are the appropriate reagents for evaluating variants that might present significant biohazards if constructed into replication-competent viruses. Second, the deletions that we constructed by SARS-CoV/SARS-CoV-2 exchanges do not have precisely the same breakpoints and lengths as the naturally occurring VOC and RDR deletions, and in these VOCs, several other S protein substitutions may operate in metastable control. Experiments with natural VOC VLPs are in progress. That stated, the findings in our study indicate that NTD deletions should be investigated in ways that go beyond their known contributions to antigenic variability (22, 72) with an additional distinct focus on their potential for establishing alternative metastable states that increase virus transmissibility.

Plasmids. Full-length SARS-CoV S (GenBank accession no. AY278741.1) and SARS-CoV-2 S, E, M, and N (GenBank accession no. NC_045512.2) genes were synthesized by GenScript, Inc., as human-codonoptimized cDNAs and inserted into pcDNA3.1 expression vectors. C9-tagged versions of the S genes were generated by replacing the 19 39-terminal codons with linker and C9 codons (GSSGGSSG-GGTETSQVAPA). HiBiT-N was constructed by fusing HiBiT peptide (VSGWRLFKKIS) coding sequences with a linker (GSSGGSSG) to the 59 end of the N gene, as described in references 42 and 43. The pCMV-LgBiT expression plasmid was purchased from Promega. pDSP 1-7 and pDSP [8] [9] [10] [11] plasmid DNAs (73, 74) were provided by Zene Matsuda (University of Tokyo). pcDNA3.1-hACE2-C9 was obtained from Michael Farzan, Scripps Florida. pCAGGS-hTMPRSS2 FLAG was constructed previously (75) . pcDNA3.1-hACE2-LgBiT was constructed by fusing the coding sequence of LgBiT to the 39 end of hACE2 gene.

Cells. HEK293T, HeLa, and HeLa-hACE2 (obtained from Ed Campbell, Loyola University Chicago) cells were maintained in Dulbecco's modified Eagle medium (DMEM)-10% fetal bovine serum (FBS) (containing 10 mM HEPES, 100 nM sodium pyruvate, 0.1 mM nonessential amino acids, 100 U/ml penicillin G, and 100 mg/ml streptomycin and supplemented with 10% FBS; Atlanta Biologicals). Calu-3 cells (obtained from Paul McCray, University of Iowa) were maintained in MEM-20% FBS (MEM supplemented with 20% FBS, 100 U/ml penicillin G, and 100 mg/ml streptomycin). All cell lines were cultured in a 5% CO 2 incubator at 37°C.

Western blotting and antibodies. Samples in SDS solubilizer (0.0625 M TrisÁHCl [pH 6.8], 10% glycerol, 0.01% bromophenol blue, and 2% [wt/vol] SDS with and without 2% 2-mercaptoethanol) were heated at 95°C for 5 min, electrophoresed through 8% or 10% (wt/vol) polyacrylamide-SDS gels, transferred to nitrocellulose membranes (Bio-Rad), and incubated with rabbit polyclonal anti-SARS-CoV-2-S1 (SinoBiological; catalog no. 40591-T62), rabbit polyclonal anti-SARS-S2 (no. JH50520001; obtained from Carolyn Machamer, Johns Hopkins University), mouse anti-C9 (EMD Millipore), mouse monoclonal antivesicular stomatitis virus (VSV) M (Kerafast; catalog no. EB0011), goat anti-human IgG (sc-2453; Santa Cruz Biotechnologies), rabbit monoclonal anti-hACE2 (Invitrogen; catalog no. MA5-32307), rabbit polyclonal anti-green fluorescent protein (GFP) (obtained from Katherine Knight, Loyola University Chicago), or purified LgBiT-substrate cocktail (Promega). After incubation with appropriate horseradish peroxidase (HRP)-tagged secondary antibodies and chemiluminescent substrate (Thermo Fisher), the blots were imaged and processed with a FluorChem E apparatus (Protein Simple).

VLPs. HiBiT-N-tagged virus-like particles (VLPs) were produced as described previously (42, 43) . Briefly, equimolar amounts of full-length CoV S, E (envelope), M (membrane), and HiBiT-N-encoding plasmids (total, 10 mg) were LipoD (SignaGen Laboratories) transfected into 10 7 HEK293T cells. To produce spikeless ("no-S") VLPs, the S expression plasmids were replaced with empty vector plasmids. At 6 h posttransfection, cells were replenished with fresh DMEM-10% FBS. HiBiT-N VLPs were collected in FBSfree DMEM from 24 to 48 h posttransfection. FBS-free DMEM containing HiBiT-N VLPs were clarified by centrifugation (300 Â g, 4°C, 10 min; 3,000 Â g, 4°C, 10 min).

To obtain purified viral particles, clarified VLP-containing FBS-free DMEM was concentrated 100-fold by ultrafiltration (Amicon; 100 kDa) and then VLPs were purified using size exclusion chromatography (SEC) (original qEV column, used according to product instructions; Izon, Inc.). VLPs were eluted from columns into 2Â FBS-free DMEM plus 0.2% FBS. Peak VLP fractions were identified after detergent lysis of VLPs by adding LgBiT and measuring complemented nanoluciferase (Nluc) in a luminometer. Peak fractions were stored at 280°C. Alternatively, VLP-containing FBS-free DMEM samples were overlaid onto 20%, wt/wt, sucrose cushions and particles purified via slow-speed pelleting (SW28, 6,500 rpm, 4°C, 24 h). The resulting pellet was resuspended in FBS-free DMEM to 1/100 of the original medium volumes. SEC peak fractions and resuspended pellets were stored at 280°C.

VLP cell entry assay. HeLa target cells were LipoD transfected with pcDNA3.1-hACE2-LgBiT and pCAGGS-TMPRSS2 FLAG . At 2 days posttransfection, cells were incubated with a live-cell Nluc substrate (Nano-Glo Endurazine; Promega), and 2 h later, HiBiT-N VLPs were inoculated at equivalent HiBiT input multiplicities. HiBiT-N VLPs lacking S proteins (no S) served as negative controls. At hourly intervals following VLP inoculation, Nluc levels were quantified using a Veritas microplate luminometer. For data presentation, the Nluc recordings in cultures inoculated with spikeless (no-S) VLPs were normalized to values of 1.0, and the fold increases over this control condition were calculated and plotted as "relative entry."

Cell-free fusion assay. Cell-free fusion assays required ACE2-LgBiT EVs. To obtain these EVs, HEK293T target cells were LipoD transfected with pcDNA3.1-hACE2-LgBiT. At 6 h posttransfection, transfection media were removed, rinsed, and replaced with FBS-free DMEM. Media were collected at 48 h posttransfection, clarified (300 Â g, 4°C, 10 min; 3,000 Â g, 4°C, 10 min), and concentrated 100-fold by ultrafiltration (Amicon; 100 kDa). EVs were then purified using SEC (qEV original; Izon, Inc.) using phosphate-buffered saline (PBS; pH 7.4) as the eluant. Peak EV fractions were identified by the addition of HiBiT-containing detergent and subsequent Nluc measurement by luminometry. EVs were stored at 4°C.

Cell-free fusion assays were performed by mixing HiBiT-N VLPs, each introduced at equivalent HiBiT concentrations, with hACE2-LgBiT EVs, the NanoLuc substrate (catalog no. N2420; Promega), and trypsin (Sigma; 10 ng/ml or as indicated) in 384-well multiwell plates. After 5 min at 4°C, sample plates were loaded into a GloMax luminometer maintained at 37°C. VLP-EV cell-free fusions were quantified as Nluc accumulations over time. For data presentation, the Nluc recordings from samples containing control spikeless (no-S) VLPs were normalized to values of 1.0, and the fold increases over levels for this control condition were calculated and plotted as fold fusion.

For experiments involving S-binding fusion inhibitors, VLPs were premixed at 4°C with serial dilutions of either hACE2:Fc or antibody 576.4 (anti-RBD-antibody, obtained from Hans-Martin Jäck, Friedrich-Alexander-Universität) and then incubated for 30 min at 37°C before the addition of EVs, the substrate, and trypsin. For thermal inactivation experiments, VLPs were preincubated for 0, 24, or 41 h at 37°C, before being mixed with EVs, the substrate, and trypsin at 4°C.

Pseudoviruses. Pseudovirus particles (PPs) were constructed from a VSV platform, as described in reference 76. Briefly, HEK293T cells were LipoD transfected for 6 h with S-C9 tag expression plasmids and then replenished with fresh DMEM-10% FBS. At 1 day posttransfection, cells were inoculated for 2 h with VSVdeltaG/Junin GP-luciferase (VSV-luc PP [42, 77] ), rinsed extensively, and then replenished with DMEM-10% FBS. Conditioned media were collected 2, 3, and 4 days posttransfection, debris was removed by centrifugation (300 Â g, 4°C, 10 min; 3,000 Â g, 4°C, 10 min), and then PPs were pelleted through 20%, wt/wt, sucrose cushions (SW28, 6,500 rpm, 4°C, 24 h) and resuspended in FBS-free DMEM to 1/100 of the original medium volumes. Concentrated PP stocks were stored at 280°C.

Pseudovirus entry assays. VSV PPs were inoculated onto Calu-3 cells for 6 h with or without Fc constructs, rinsed extensively, and replenished with FBS-containing DMEM or MEM. At 16 h postransduction, cells were dissolved in lysis buffer (25 mM Fc constructs. pCEP4-mCEACAM:Fc was constructed previously (78) . Additional constructs were generated using the strategy described in reference 42. Briefly, the mCEACAM coding region was removed by NotI and MreI digestion and replaced with the SARS-CoV-2 S NTD (codons 1 to 309), SARS-CoV-2 NTD-2/1, SARS-CoV-2 S RBD (codons 1 to 24 from the hCD5 signal sequence followed by SARS-CoV-2 S codons 310 to 529), or hACE2 ectodomain (codons 1 to 740). The expression plasmids were LipoD transfected into HEK293T cells, and transfected cells were incubated in FBS-free DMEM containing 2% (wt/vol) Cell Boost 5 (HyClone). Conditioned media were collected on days 4 and 7 and clarified free of debris (300 Â g, 4°C, 10 min; 4,500 Â g, 4°C, 10 min), and Fc-tagged proteins were then purified using HiTrap protein A high-performance columns (GE Healthcare) according to the manufacturer's instructions. Purified proteins were dialyzed in PBS (pH 7.4), quantified spectrophotometrically, and stored at 220°C until use.

Cell-cell fusion assay. Effector and target cells were prepared as described previously (42) . Briefly, effector HeLa cells were cotransfected with pDSP 1-7 and pcDNA3.1-SARS-CoV-2-S-C9. Control effector cells received pDSP 1-7 and empty vector plasmids. Target cells (HeLa or HeLa-hACE2) were cotransfected with pDSP [8] [9] [10] [11] and the indicated hACE2-and/or TMPRSS2 -expressing plasmids. At 30 h posttransfection, target cells were suspended and replated into white-walled 96-well plates. Sixteen hours later, a live-cell Renilla luciferase (Rluc) substrate (EnduRen; Promega) and the indicated concentrations of Fc proteins were added. After 2 h, suspended effector cells were distributed into the wells. At hourly intervals following the cocultivation of target and effector cells, Rluc levels were quantified using a Veritas microplate luminometer.

Statistical analysis. Statistical comparisons were made by the unpaired Student t test. Error bars indicate the standard errors (SE) of the data. P values of less than 0.05 were considered statistically significant.

Supplemental material is available online only. 

A pneumonia outbreak associated with a new coronavirus of probable bat origin

The proximal origin of SARS-CoV-2

Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus

SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity

The variant gambit: COVID-19's next move

Infection of human nasal epithelial cells with SARS-CoV-2 and a 382-nt deletion isolate lacking ORF8 reveals similar viral kinetics and host transcriptional profiles

Single cell resolution of SARS-CoV-2 tropism, antiviral responses, and susceptibility to therapies in primary human airway epithelium

SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract

Receptor recognition mechanisms of coronaviruses: a decade of structural studies

Coronavirus spike protein and tropism changes

Two-step conformational changes in a coronavirus envelope glycoprotein mediated by receptor binding and proteolysis

Structure, function, and evolution of coronavirus spike proteins

Distinct conformational states of SARS-CoV-2 spike protein

Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion

Pre-fusion structure of a human coronavirus spike protein

Cryo-EM analysis of the post-fusion structure of the SARS-CoV spike glycoprotein

Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding

Enhanced virulence mediated by the murine coronavirus, mouse hepatitis virus strain JHM, is associated with a glycine at residue 310 of the spike glycoprotein

Mutations in the spike protein of Middle East respiratory syndrome coronavirus transmitted in Korea increase resistance to antibody-mediated neutralization

Spike mutation D614G alters SARS-CoV-2 fitness

Comparative phylogenetic analysis of SARS-CoV-2 spike protein-possibility effect on virus spillover

Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Cell entry mechanisms of SARS-CoV-2

A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells

Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy

Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding

The N-terminal domain of spike glycoprotein mediates SARS-CoV-2 infection by associating with L-SIGN and DC-SIGN

HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry

SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2

The SARS-COV-2 spike protein binds sialic acids and enables rapid detection in a lateral flow point of care diagnostic device

Bioinformatics studies on a function of the SARS-CoV-2 spike glycoprotein as the binding of host sialic acid glycans

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2

Structural impact on SARS-CoV-2 spike protein by D614G substitution

Coronavirus biology and replication: implications for SARS-CoV-2

Neutralization-resistant variants of a neurotropic coronavirus are generated by deletions within the amino-terminal half of the spike glycoprotein

Variations in disparate regions of the murine coronavirus spike protein impact the initiation of membrane fusion

Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

Distinct roles for sialoside and protein receptors in coronavirus infection

Assembly and entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2): evaluation using virus-like particles

Implication of proprotein convertases in the processing and spread of severe acute respiratory syndrome coronavirus

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Extracellular vesicles containing ACE2 efficiently prevent infection by SARS-CoV-2 spike protein-containing virus

Real-time conformational dynamics of SARS-CoV-2 spikes on virus particles

Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains

Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion

Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites

Structures of MERS-CoV spike glycoprotein in complex with sialoside attachment receptors

Structural basis for human coronavirus attachment to sialic acid receptors

Crystal structure of mouse coronavirus receptor-binding domain complexed with its murine receptor

Localization of neutralizing epitopes and the receptor-binding site within the amino-terminal 330 amino acids of the murine coronavirus spike protein

Receptor-induced conformational changes of murine coronavirus spike protein

Difference in Bgp-independent fusion activity among mouse hepatitis viruses

Two mutations were critical for bat-to-human transmission of Middle East respiratory syndrome coronavirus

Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice

Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction

Identification of common deletions in the spike protein of severe acute respiratory syndrome coronavirus 2

Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant

The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways

Broad neutralization of SARS-related viruses by human monoclonal antibodies

Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity

SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo

How SARS-CoV-2 first adapted in humans

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus

Interactions of LSECtin and DC-SIGN/DC-SIGNR with viral ligands: differential pH dependence, internalization and virion binding

Crystal structure of bovine coronavirus spike protein lectin domain

Structure-function analyses of new SARS-CoV-2 variants B.1.1.7, B.1.351 and B.1.1.28.1: clinical, diagnostic, therapeutic and public health implications

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Development of a rapid cell-fusion-based phenotypic HIV-1 tropism assay

Dual split protein (DSP) assay to monitor cellcell membrane fusion

A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry

Generation of VSV pseudotypes using recombinant Del-taG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines

Evaluating MERS-CoV entry pathways

A role for naturally occurring variation of the murine coronavirus spike protein in stabilizing association with the cellular receptor

This research was supported by the National Institutes of Health (NIH) under award P01 AI060699 (to S.P.). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.We thank Hans-Martin Jäck (Freidrich-Alexander University at Erlangen-Nürnberg) for SARS-CoV-2 RBD MAb 567.4. We thank Bryan Mounce and Susan Baker (Loyola University Chicago) and Paul McCray (University of Iowa) for critical reading of the manuscript.